36U0.F OPTOMED OY A EO 005
- Market cap
- EUR 35.1M
- P/E
- -
- P/B
- 1.67x
- ROE
- -9.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 36U0.F undervalued?
Graham numberThe Graham number of OPTOMED OY A EO 005 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OPTOMED OY A EO 005 fundamental analysis
No fundamental analysis for OPTOMED OY A EO 005 yet.
OPTOMED OY A EO 005 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OPTOMED OY A EO 005
Optomed Oyj, together with its subsidiaries, manufactures and sells handheld fundus cameras in Finland, rest of Europe, and internationally. The company operates in two segments, Devices and Software. It develops, manufactures, and sells fundus cameras for ophthalmologists, pediatricians, endocrinologists, neurologists, and primary health care professionals; and provides professional IT consulting services for government institutions. The company also provides camera product…
Full company profileOPTOMED OY A EO 005 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OPTOMED OY A EO 005 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 14.9M | 14.7M | 15.1M | 15.0M | 17.1M | 16.1M |
| Gross Profit | 9.75M | 9.21M | 10.2M | 9.67M | 10.9M | 11.2M |
| Operating Income | -4.37M | -5.10M | -3.97M | -5.96M | -6.04M | -2.83M |
| EBITDA | - | -2.29M | -2.12M | -2.86M | -4.09M | 1.03M |
| Net Income | -4.25M | -5.47M | -4.44M | -5.45M | -6.64M | -2.08M |
| EPS | -0.31 | -0.34 | -0.25 | -0.28 | -0.31 | -0.10 |
| Balance Sheet | ||||||
| Total Assets | 29.0M | 31.3M | 29.1M | 31.8M | 32.0M | 29.4M |
| Total Liabilities | 11.9M | 11.0M | 8.72M | 8.14M | 7.96M | 7.13M |
| Shareholders' Equity | 17.1M | 20.3M | 20.4M | 23.6M | 24.0M | 22.3M |
| Cash & Short-term Investments | 6.80M | 8.52M | 7.12M | 10.5M | 9.91M | 6.99M |
| Cash Flow | ||||||
| Operating Cash Flow | -2.94M | -2.37M | -615K | -1.60M | -2.48M | -907K |
| Capital Expenditure | 2.57M | 3.03M | 2.41M | 2.12M | 2.36M | 2.18M |
| Free Cash Flow | -5.51M | -5.40M | -3.03M | -3.71M | -4.84M | -3.08M |
| Ratios | ||||||
| ROE | -24.9% | -26.9% | -21.8% | -23.1% | -27.6% | -9.3% |
| ROA | -14.7% | -17.5% | -15.3% | -17.1% | -20.8% | -7.1% |
| Net Profit Margin | -28.6% | -37.3% | -29.4% | -36.2% | -38.8% | -12.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OPTOMED OY A EO 005 dividends
OPTOMED OY A EO 005 has not paid dividends in the last 5 fiscal years.
Who owns OPTOMED OY A EO 005
- Insiders 5.63%
- Institutions 28.75%
- Public & others 65.62%
- Shares outstanding 21.5M
- Free float 20.8M
OPTOMED OY A EO 005 company profile
- Company name
- OPTOMED OY A EO 005
- Ticker
- 36U0.F
- ISIN
- FI4000410881
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 110
- Fiscal year end
- December
- Address
- Yrttipellontie 1, Oulu, Finland, 90230
- Phone
- 358 2074 13380
- Website
- optomed.com
About OPTOMED OY A EO 005
Optomed Oyj, together with its subsidiaries, manufactures and sells handheld fundus cameras in Finland, rest of Europe, and internationally. The company operates in two segments, Devices and Software. It develops, manufactures, and sells fundus cameras for ophthalmologists, pediatricians, endocrinologists, neurologists, and primary health care professionals; and provides professional IT consulting services for government institutions. The company also provides camera products under the Optomed Smartscope Pro, Optomed Aurora, Optomed Aurora AEYE, Optomed Polaris, and Optomed Lumo brand names, as well as OEM cameras under the Volk Optical, Carl Zeiss Meditec, and Topcon brands. The company provides Avenue AI, an AI streamlines eye specialists' work and minimises screening costs; Avenue Eye Screen, a workflow management software for screening and monitoring of eye diseases; Avenue Flow, an eyecare management software; and Avenue Telemedicine, a remote analysis solution. In addition, it offers Cancer Screen, a screening process management software; Optomed Radiology Information System, a software solution for healthcare imaging units; Sectra PACS, a modular system for healthcare providers; Optomed Service Portal, a support function for healthcare units; Cephalometry, a powerful, flexible, and easy-to-use Windows software for orthodontics, oral and maxillofacial surgery; and Pathology PACS, which allows digital pathology images to be reviewed and shared. Optomed Oyj was incorporated in 2004 and is headquartered in Oulu, Finland.
OPTOMED OY A EO 005 management
3- Mr. Juho HimbergChief Executive Officer · born 1970
- Mr. Sakari KnuuttiCFO, Chief Legal Officer & Secretary of the Board · born 1984
- Mr. Seppo Henrik KopsalaFounder · born 1978